Cipla sharpens focus on core therapies

Cipla, the pharmaceuticals major, is exiting non-core businesses to build a stronger pipeline in its key therapies on offer, of respiratory, oncology and anti-HIV drugs. 

This comes at a time when it faces pricing pressure in both India and America. The move will mean more capital for key growth areas and reduce investment risk.

One step is the decision to scale down the biotechnology business. Last week, Cipla said it would not manufacture biosimilars. It also put on hold an earlier plan for a manufacturing unit in South Africa. The announcement was made after a Rs 62 crore loss in